SEC Info - Golden Ally Lifetech Group, Inc.

Page	(sequential)		(alphabetic)	↑Top
		Alternative Formats (Word, et al.) Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 Condensed Consolidated Statements of Stockholders' Equity (Deficit) as of June 30, 2022 and 2021 Controls and Procedures Defaults Upon Senior Securities Exhibits Financial Statements (unaudited) Legal Proceedings Management's Discussion and Analysis of Financial Condition and Results of Operations Mine Safety Disclosures Notes to Condensed Consolidated Financial Statements Other Information Quantitative and Qualitative Disclosures About Market Risk Risk Factors Signatures Unregistered Sales of Equity Securities and Use of Proceeds
1	1st Page – Filing Submission
"	Financial Statements (unaudited)
"	Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021
"	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021
"	Condensed Consolidated Statements of Stockholders' Equity (Deficit) as of June 30, 2022 and 2021
"	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021
"	Notes to Condensed Consolidated Financial Statements
"	Management's Discussion and Analysis of Financial Condition and Results of Operations
"	Quantitative and Qualitative Disclosures About Market Risk
"	Controls and Procedures
"	Legal Proceedings
"	Risk Factors
"	Unregistered Sales of Equity Securities and Use of Proceeds
"	Defaults Upon Senior Securities
"	Mine Safety Disclosures
"	Other Information
"	Exhibits
"	Signatures

i 0001317833 i false i Q2 i --12-31 i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i 0001317833 2022-01-01 2022-06-30 0001317833 2022-08-12 0001317833 2022-06-30 0001317833 2021-12-31 0001317833 AQPW:ConvertibleSeriesAPreferredStockMember 2022-06-30 0001317833 AQPW:ConvertibleSeriesAPreferredStockMember 2021-12-31 0001317833 2022-04-01 2022-06-30 0001317833 2021-04-01 2021-06-30 0001317833 2021-01-01 2021-06-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2021-12-31 0001317833 us-gaap:CommonStockMember 2021-12-31 0001317833 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001317833 us-gaap:RetainedEarningsMember 2021-12-31 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2020-12-31 0001317833 us-gaap:CommonStockMember 2020-12-31 0001317833 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001317833 us-gaap:RetainedEarningsMember 2020-12-31 0001317833 2020-12-31 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2022-01-01 2022-06-30 0001317833 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001317833 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2021-01-01 2021-06-30 0001317833 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001317833 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2022-06-30 0001317833 us-gaap:CommonStockMember 2022-06-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001317833 us-gaap:RetainedEarningsMember 2022-06-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2021-06-30 0001317833 us-gaap:CommonStockMember 2021-06-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001317833 us-gaap:RetainedEarningsMember 2021-06-30 0001317833 2021-06-30 0001317833 AQPW:SeriesAConvertibleSuperPreferredStockMember AQPW:SharePurchaseAndExchangeAgreementMember 2022-06-30 0001317833 us-gaap:CommonStockMember AQPW:SharePurchaseAndExchangeAgreementMember 2022-06-30 0001317833 us-gaap:CommonStockMember AQPW:SharePurchaseAndExchangeAgreementMember 2022-01-01 2022-06-30 0001317833 AQPW:SharePurchaseAndExchangeAgreementMember 2022-01-01 2022-06-30 0001317833 AQPW:LegalServiceMember 2022-01-01 2022-06-30 0001317833 AQPW:LegalServiceMember 2022-06-30 0001317833 2022-05-15 0001317833 2022-06-01 0001317833 AQPW:AsiaHybridCryptocurrencyLimitedMember 2021-12-01 0001317833 AQPW:AsiaHybridCryptocurrencyLimitedMember 2021-11-30 2021-12-01 0001317833 2022-04-06 0001317833 us-gaap:SeriesAPreferredStockMember 2022-04-06 0001317833 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001317833 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001317833 2021-01-01 2021-12-31 0001317833 stpr:TX 2022-01-01 2022-06-30 0001317833 country:CA 2022-01-01 2022-06-30 0001317833 us-gaap:SubsequentEventMember AQPW:TaucoinAssetManagementLLCMember 2022-07-01 2022-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. i Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). i Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ i No ☒

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis together with our financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and other reports we filed with the Securities and Exchange Commission. This Quarterly Report on Form 10-Q contains statements that discuss future events or expectations, projections of results of operations or financial condition, trends in our business, business prospects and strategies and other “forward-looking” information. In some cases, you can identify “forward-looking statements” by words like “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential” or “continue” or the negative of those words and other comparable words. These statements may relate to, among other things, our ability to implement and fund our business plan; expectations for our financial results, revenue, operating expenses and other financial measures in future periods; and the adequacy of our sources of liquidity to satisfy our working capital needs, capital expenditures, and other liquidity requirements.

On February 28, 2022, Signet International Holdings, Inc. (“Signet”),‎ Estate of Ernest W. Letiziano, Ms. Hope Hillabrand, and Mr. Thomas Donaldson ‎‎(collectively, the “Controlling Shareholders”) and Golden Ally Lifetech Group Co., Ltd., a Delaware corporation (“Golden Ally”) entered into a Share Purchase and Exchange Agreement (the “SPA”).

Under the SPA, the Controlling Shareholders agreed to exchange their capital stock of Signet, consisting of 5,000,000 shares of Series A Convertible Super Preferred Stock (convertible into 50,000,000 common shares), 4,474,080 common shares, and $375,000‎ cash for all the shares of Golden Ally (the “Purchase”).

The Purchase contemplated by the SPA was consummated on April 6, 2022. Immediately after the Closing, the former stockholders of Golden Ally Sub collectively hold beneficially and of record over 99% of the total issued and outstanding equity securities and voting power of Signet. The Purchase resulted in Golden Ally becoming a subsidiary of Signet and the shareholders of Golden Ally holding shares of Signet.

In March 2022 Signet’s Board of Directors approved, among other things, an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, subject to stockholder approval. Stockholder approval was obtained through written consent. On July 8, 2022, Golden Ally was merged with and into Signet and Signet’s name was from “Signet International Holdings, Inc.” to “Golden Ally Lifetech Group, Inc.” In this report references to “Golden Ally” or the “Company” refer to the operations and assets of the Company on a post-purchase basis.

Golden Ally is focused on its Aquaporin (“AQP”) Active Water project, which is a derivative of an academic inspiration from the 2003 Nobel Laureates in Chemistry, Dr. Peter Agre and Dr. Roderick MacKinnon jointly, “for discoveries concerning channels in cell membranes”. Golden Ally has been working closely with experienced field experts and top scientific research institutions to apply the famous Nobel Prize theory of aquaporins into its commercialized products, i.e., the AQP Active Water.

AQP Active Water is the product of a unique water filtration technology derived from raw materials with exclusive access by Golden Ally. The advanced technology can enhance water filtration for better body cell absorption to improve health. All AQP Active Water products are expected to be produced through OEM arrangements and their distribution logistics will also be supported by the OEM partners.

AQP Active Water is an epoch-making product. Consumption for a prolonged period is foreseen to possibly extend human body cells’ lifespan. Golden Ally has been running laboratory tests on its products at the David Geffen School of Medicine at University of California, Los Angeles.

High-income households are Golden Ally’s targeted consumers due to a strong correlation between income level and health spending. The global consumer pool for AQP Active Water is estimated at 17.61 million households. These households represent the portion that has an annual household income of over $150,000 USD, a level that can potentially support annual household spending on healthcare products.

Golden Ally is a developmental stage company that is currently implementing its business plan, which is to be a high-tech start-up focused on a unique product offering. Our activities to date have focused on the development and exploration of water filtration technology and consumer products with AQP Active Water. We have been working with field experts and research institutions to apply and explore the ability to enhance water filtration for improved body cell absorption in commercialized water products. During the quarter ended June 30, 2022, the Company continued taking steps to implement its business plan, including negating various agreements related to the production, marketing and distribution of its products, including a Bottling Agreement with Azure Water Bottling of Florida, LLC.

We have had limited operations and have been issued a “going concern” opinion by our auditor for the year ended December 31, 2021, based on our lack of an established source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. As of June 30, 2022, we have incurred a cumulative deficit of $3,605,708. There is limited historical financial information about us upon which to base an evaluation of our performance. We have not generated any revenues from operations. We cannot guarantee that we will be successful in our business operations.

Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays in developing our products and market downturns.

In the six months ended June 30, 2022, Golden Ally received $5,042,000 for stock subscriptions receivable related to its Common Stock. We expect to require further investments and have no assurance that future financings will be available to us on acceptable terms, or at all. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing could result in additional dilution to existing shareholders. If we are unable to raise additional capital to maintain our operations in the future, we may be unable to carry out our business plans or we may be forced to cease operations.

Our financial statements have been prepared on a going concern basis which assumes Golden Ally will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. No revenues have been generated to date and we expect limited revenues.

During the three and six months ended June 30, 2022, we did not generate any revenue. Our operating expenses for the three and six month periods ended June 30, 2022 were $1,586,388 and $3,548,138, consisting primarily of professional fees and other expenses paid to develop and implement marketing strategies for its products. and wages and salaries for Company personnel. As a result, for the three and six months ended June 30, 2022 we incurred a loss from operations of $1,586,388 and $3,548,138. During the three and six months ended June 30, 2021 we did not have any operations.

Working Capital and Cash Flows. Golden Ally used cash flows of $3,747,918 for‎ operating activities for the six months ended June 30, 2022.

On January 3, 2022, Golden Ally entered into an agreement with a company owned by a related party, Taucoin Asset Management LLC, to develop and implement marketing strategies for its products. During the first six months of 2022, the Company paid a total of $1,800,000 on this agreement.

On January 18, 2022, Golden Alley entered into an agreement for legal services. In January 2022, Golden Ally paid $500,000 as a retainer to the legal service provider.

Golden Ally has a lease for an office in Texas for one year at $332 per month. During the six months ended June 30, 2022, the Company also entered into a lease for a location in California. The initial term of the lease was four months ending on May 31, 2022. The lease was renewed on June 1, 2022, and the base rent is now $6,300 per month.

In July 2022, the Company paid a related party, Taucoin Asset Management LLC, additional amounts of $200,000 and $400,000 to develop and implement marketing strategies for Company products.

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“GAAP”). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures in our financial statements. We had no critical accounting policies for the year ended December 31, 2021, or for the quarter ended June 30, 2022.

We have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are summarized in Note 3 to our financial statements. Although we believe that our estimates, judgments and assumptions are reasonable, they are based upon information presently available. Actual results may differ from those estimates.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is collected and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for our Company. In designing and evaluating our disclosure controls and procedures, management recognizes that no matter how well conceived and operated, disclosure controls and procedures can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our “disclosure controls and procedures” (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q (the “Evaluation Date”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

** The certifications attached as Exhibits 32.1 and 32.2 that accompanies this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

+ Certain portions of this agreement have been omitted because such information is not material and is the type that the registrant treats as private or confidential.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

i ☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended i June 30, i 2022 /

or

i ☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to________

Large accelerated filer	☐	Accelerated Filer	☐
i Non-accelerated filer	☒	Smaller reporting company	i ☒
Emerging growth company	i ☐

	June 30, 2022			December 31, 2021

Assets
Current
Cash	$	i 2,914,914		$	i 2,999,370
Prepaids		i 227,017			-
Loan receivable – related party		i 1,000,000			-
Total Current Assets		i 4,141,931			i 2,999,370

Right of use asset		i 132,451			-
Goodwill		i 1,777,204			-
Total Assets	$	i 6,051,586		$	i 2,999,370

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued liabilities	$	i 21,478		$	-
Lease liabilities		i 75,600			-
Due to related parties		i 5,000			i 5,000
Total Current liabilities		i 102,078			i 5,000

Lease liability, net of current portion		i 57,362			-
Total Liabilities		i 159,440			i 5,000

Stockholders’ Equity

Convertible Series A Preferred Stock, par value $ i i 0.00001 / : i i 1,000,000,000 / authorized; i 1,000,000,000 and i 5,000,000 outstanding		i 10,000			i 50
Common Stock, par value $ i i 0.00001 / ; i i 10,000,000,000 / authorized; i 8,496,061,902, and i 20,535,982 outstanding		i 84,961			i 205
Additional paid-in capital		i 9,402,893			i 3,051,685
Accumulated deficit		( i 3,605,708	)		( i 57,570	)
Total Stockholders’ Equity		i 5,892,146			i 2,994,370

Total Liabilities and Stockholders’ Equity	$	i 6,051,586		$	i 2,999,370

	2022			2021		2022			2021
	For the Three Months Ended June 30,					For the Six Months Ended June 30,
	2022			2021		2022			2021

Operating Expenses
Amortization	$	i 5,759			-	$	i 5,759		$	-
Financing and interest		i 1,052			-		i 1,052			-
General and administrative		i 60,606			-		i 217,152			-
Professional fees		i 1,107,649			-		i 2,501,532			-
Wages and salaries		i 411,322			-		i 822,643			-
Total Operating Expenses		i 1,586,388					i 3,548,138			-

Net operating loss	$	( i 1,586,388	)	$	-		( i 3,548,138	)		-
Income tax		-			-		-			-
Net Loss	$	( i 1,586,388	)	$	-	$	( i 3,548,138	)	$	-

Loss per Common Share	$	( i 0.00	)	$	-	$	( i 0.00	)	$	-

Weighted Average Common Shares Outstanding		i 7,937,236,017			i 20,535,982		i 4,000,642,954			i 20,535,982

	2022			2021
	For the Six Months Ended June 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES

Net loss	$	( i 3,548,138	)	$	-
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization		i 5,759
Prepaids		( i 227,017	)
Accounts payable and accrued liabilities		i 21,478
Net cash used in Operating Activities		( i 3,747,918	)

CASH FLOWS FROM FINANCING ACTIVITIES
Payment of lease lability		( i 5,248	)
Proceeds from issuance of common shares		i 5,042,060
Loan receivable – related party		( i 1,000,000	)
Net cash provided by Financing Activities		i 4,036,812

CASH FLOWS USED IN INVESTING ACTIVITIES
Cash paid in reverse merger		( i 373,350	)
Net cash used in Investing Activities		( i 373,350	)

Net change in cash		( i 84,456	)
Cash - Beginning of period		i 2,999,370
Cash - End of period	$	i 2,914,914		$	-

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	-

NON CASH INVESTING AND FINANCING ACTIVITIES:
Value of shares not exchanged in reverse merger	$	i 1,403,854		$	-
Issuance of Stock - Preferred Series A and Common	$	-		$	-

Golden Ally Lifetech Group, Inc. – ‘10-Q’ for 6/30/22

On: Thursday, 8/18/22, at 5:24pm ET · For: 6/30/22 · Accession #: 1493152-22-23491 · File #: 0-51185

Previous ‘10-Q’: ‘10-Q’ on 5/23/22 for 3/31/22 · Next: ‘10-Q’ on 11/21/22 for 9/30/22 · Latest: ‘10-Q’ on 5/15/23 for 3/31/23 · 2 References:

Quarterly Report — Form 10-Q

Filing Table of Contents

‘10-Q’ — Quarterly Report

Document Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

1 Subsequent Filing that References this Filing

1 Previous Filing that this Filing References

Title of each class		Trading symbol(s)		Name of each exchange on which registered

			Page

PART I. FINANCIAL INFORMATION

	Item 1.	Financial Statements (unaudited)	3

		Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021	3

		Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021	4

		Condensed Consolidated Statements of Stockholders’ Equity (Deficit) as of June 30, 2022 and 2021	5

		Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021	6

		Notes to Condensed Consolidated Financial Statements	7

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14

	Item 4.	Controls and Procedures	14

PART II. OTHER INFORMATION

	Item 1.	Legal Proceedings	15

	Item 1A.	Risk Factors	15

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15

	Item 3.	Defaults Upon Senior Securities	15

	Item 4.	Mine Safety Disclosures	15

	Item 5.	Other Information	15

	Item 6.	Exhibits	15

SIGNATURES			16

	●	Golden Ally Lifetech Group, Inc., through their ownership of the Convertible Series A Preferred stock and Common Stock, has a i 77% of the voting interest;

	●	Golden Ally Lifetech Group, Inc., selected all of the new board of directors of Signet;

	●	Golden Ally Lifetech Group, Inc., senior management is the senior management of Signet; and

	●	Golden Ally Lifetech Group, Inc., is the larger entity based on historical operating activity.

EXHIBIT NO.		DESCRIPTION
3.1		Certificate of Ownership and Merger dated July 8, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report dated July 8, 2022)
10.1+		Bottling Agreement between Golden Ally Lifetech Group, Inc. and Azure Water Bottling of Florida, LLC dated June 24, 2022
31.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

Date:	August 18, 2022	Signet International Holdings, Inc.

		By:	/s/ Oliver Keren Ban
			Oliver Keren Ban, Chief Executive Officer and President (Principal Executive Officer), Secretary, Treasurer, and Director

		By:	/s/ Tak Yiu Cheng
			Tak Yiu Cheng, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

This ‘10-Q’ Filing	Date	Other Filings

	1/31/23
	11/14/22
Filed on:	8/18/22
	8/12/22
	7/8/22	8-K
For Period end:	6/30/22	8-K, NT 10-Q
	6/1/22
	5/31/22
	5/15/22
	4/6/22	3, 8-K
	3/16/22	DEF 14C
	3/7/22
	2/28/22	8-K
	1/19/22
	1/18/22
	1/3/22
	12/31/21	10-K
	12/1/21
	6/30/21	10-Q
	12/31/20	10-K
	12/1/20
	2/2/05
		List all Filings